A recent study conducted by Lund University in Sweden has resolved a long-standing mystery: identifying which patients with aggressive breast cancer benefit from a targeted cancer treatment that was previously under development but had been discontinued. This breakthrough is significant, offering renewed hope that the drug’s development can resume and ultimately reach the patients who […]
Source link
